Lee S. Schwartzberg
- Oncology top 0.2%
- Cancer Treatment and Pharmacology 94
- HER2/EGFR in Cancer Research 48
- Colorectal Cancer Treatments and Studies 46
- Hematology top 0.5%
- Cancer Research top 1%
- Breast Cancer Treatment Studies 56
- Cancer Genomics and Diagnostics 50
- Pulmonary and Respiratory Medicine top 0.5%
- Lung Cancer Treatments and Mutations 64
- Advanced Breast Cancer Therapies 53
-
- Nausea and vomiting management 77
- Co-authors
- Rudolph M. NavariArthur C. HoutsRobert BirchB HazeltonMark S. WalkerBarry FortnerCathy AllenW. H. West
- Cited by
- OncologyHematologyCancer Research
- Partner nations
- United StatesGermanyUnited Kingdom
In The Last Decade
Lee S. Schwartzberg
402 papers receiving 9.9k citations
Hit Papers
Peers
Comparison fields: 5 of 142
- Oncology 6.0k
- Hematology 1.5k
- Cancer Research 1.5k
- Pulmonary and Respiratory Medicine 2.3k
- Anesthesiology and Pain Medicine 393
Countries citing papers authored by Lee S. Schwartzberg
This map shows the geographic impact of Lee S. Schwartzberg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lee S. Schwartzberg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lee S. Schwartzberg more than expected).
Fields of papers citing papers by Lee S. Schwartzberg
This network shows the impact of papers produced by Lee S. Schwartzberg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lee S. Schwartzberg. The network helps show where Lee S. Schwartzberg may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Lee S. Schwartzberg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 3 | |
| 3 | 2024 | 1 | |
| 4 | 2023 | 9 | |
| 5 | 2023 | 1 | |
| 6 | 2023 | 3 | |
| 7 | 2022 | 7 | |
| 8 | 2022 | 6 | |
| 9 | 2020 | 16 | |
| 10 | 2020 | 12 | |
| 11 | 2019 | 17 | |
| 12 | 2018 | 9 | |
| 13 | 2017 | 42 | |
| 14 | 2017 | 166 | |
| 15 | PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancerbreakdown → | 2014 | 478 |
| 16 | Payer and provider collaborations that improve quality outcomes in oncology. | 2010 | 1 |
| 17 | 2008 | 250 | |
| 18 | A prospective investigation of chemotherapy-induced neutropenia and quality of life. | 2006 | 11 |
| 19 | 1998 | 10 | |
| 20 | 1998 | 51 |
About Lee S. Schwartzberg
Lee S. Schwartzberg is a scholar working on Oncology, Cancer Research and Family Practice, having authored 422 papers that have together received 10.2k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (94 papers), Nausea and vomiting management (77 papers), Lung Cancer Treatments and Mutations (64 papers), Breast Cancer Treatment Studies (56 papers), Advanced Breast Cancer Therapies (53 papers), Cancer Genomics and Diagnostics (50 papers), HER2/EGFR in Cancer Research (48 papers) and Colorectal Cancer Treatments and Studies (46 papers). The work is most often cited by research in Oncology (6.0k citations), Hematology (1.5k citations) and Cancer Research (1.5k citations). Lee S. Schwartzberg has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Rudolph M. Navari, Arthur C. Houts, Robert Birch, B Hazelton, Mark S. Walker, Barry Fortner, Cathy Allen, W. H. West, Meinolf Karthaus and C H Weaver. Their work appears in journals such as Journal of Clinical Oncology, Blood and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.